Altshuler Shaham LTD Abb Vie Inc. Transaction History

Altshuler Shaham LTD

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	SELL	$144.61 - $166.54 $53,794 - $61,952	-372 Reduced 57.32%	277 $44,000
Q4 2022 May 09, 2023	SELL	$138.31 - $165.87 $22,406 - $26,870	-162 Reduced 19.98%	649 $104,000
Q3 2022 Nov 14, 2022	SELL	$134.21 - $153.93 $90,725 - $104,056	-676 Reduced 45.46%	811 $116,000
Q2 2022 Aug 10, 2022	SELL	$137.62 - $174.96 $2.19 Million - $2.79 Million	-15,940 Reduced 91.47%	1,487 $228,000
Q1 2022 May 16, 2022	BUY	$131.98 - $163.75 $176,061 - $218,442	1,334 Added 8.29%	17,427 $2.83 Million
Q4 2021 Feb 15, 2022	SELL	$107.43 - $135.93 $6,123 - $7,748	-57 Reduced 0.35%	16,093 $2.18 Million
Q3 2021 Nov 15, 2021	BUY	$106.4 - $120.78 $1.62 Million - $1.83 Million	15,181 Added 1566.67%	16,150 $1.75 Million
Q2 2021 Aug 16, 2021	SELL	$105.21 - $117.21 $4,944 - $5,508	-47 Reduced 4.63%	969 $109,000
Q1 2021 May 13, 2021	SELL	$102.3 - $112.62 $62,914 - $69,261	-615 Reduced 37.71%	1,016 $110,000
Q4 2020 Feb 16, 2021	BUY	$80.49 - $108.67 $804 - $1,086	10 Added 0.62%	1,631 $174,000
Q3 2020 Nov 10, 2020	BUY	$85.91 - $100.83 $87,456 - $102,644	1,018 Added 168.82%	1,621 $142,000
Q2 2020 Aug 13, 2020	BUY	$73.37 - $98.18 $13,426 - $17,966	183 Added 43.57%	603 $59,000
Q1 2020 May 12, 2020	BUY	$64.5 - $97.79 $4,063 - $6,160	63 Added 17.65%	420 $32,000
Q4 2019 Feb 11, 2020	BUY	$72.13 - $90.25 $25,461 - $31,858	353 Added 8825.0%	357 $32,000
Q3 2019 Nov 12, 2019	SELL	$62.98 - $75.72 $8,124 - $9,767	-129 Reduced 96.99%	4 $0
Q2 2019 Aug 06, 2019	BUY	$65.7 - $83.98 $8,738 - $11,169	133 New	133 $10,000

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Altshuler Shaham LTD, based on Form 13F filings with the SEC.

Stay updated on Altshuler Shaham LTD with notifications on news.